Literature DB >> 21931115

Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D.

Marie Meeths1, Samuel C C Chiang, Stephanie M Wood, Miriam Entesarian, Heinrich Schlums, Benedicte Bang, Edvard Nordenskjöld, Caroline Björklund, Gordana Jakovljevic, Janez Jazbec, Henrik Hasle, Britt-Marie Holmqvist, Ljubica Rajic, Susan Pfeifer, Steen Rosthøj, Magnus Sabel, Toivo T Salmi, Tore Stokland, Jacek Winiarski, Hans-Gustaf Ljunggren, Bengt Fadeel, Magnus Nordenskjöld, Jan-Inge Henter, Yenan T Bryceson.   

Abstract

Familial hemophagocytic lymphohistiocytosis (FHL) is an autosomal recessive, often-fatal hyperinflammatory disorder. Mutations in PRF1, UNC13D, STX11, and STXBP2 are causative of FHL2, 3, 4, and 5, respectively. In a majority of suspected FHL patients from Northern Europe, sequencing of exons and splice sites of such genes required for lymphocyte cytotoxicity revealed no or only monoallelic UNC13D mutations. Here, in 21 patients, we describe 2 pathogenic, noncoding aberrations of UNC13D. The first is a point mutation localized in an evolutionarily conserved region of intron 1. This mutation selectively impairs UNC13D transcription in lymphocytes, abolishing Munc13-4 expression. The second is a 253-kb inversion straddling UNC13D, affecting the 3'-end of the transcript and likewise abolishing Munc13-4 expression. Carriership of the intron 1 mutation was found in patients across Europe, whereas carriership of the inversion was limited to Northern Europe. Notably, the latter aberration represents the first description of an autosomal recessive human disease caused by an inversion. These findings implicate an intronic sequence in cell-type specific expression of Munc13-4 and signify variations outside exons and splice sites as a common cause of FHL3. Based on these data, we propose a strategy for targeted sequencing of evolutionary conserved noncoding regions for the diagnosis of primary immunodeficiencies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21931115     DOI: 10.1182/blood-2011-07-369090

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

1.  Functional and genetic testing in adults with HLH reveals an inflammatory profile rather than a cytotoxicity defect.

Authors:  Julien Carvelli; Christelle Piperoglou; Catherine Farnarier; Frédéric Vely; Karin Mazodier; Sandra Audonnet; Patrick Nitschke; Christine Bole-Feysot; Mohamed Boucekine; Audrey Cambon; Mohamed Hamidou; Jean-Robert Harle; Geneviève de Saint Basile; Gilles Kaplanski
Journal:  Blood       Date:  2020-07-30       Impact factor: 22.113

2.  Brief Report: Novel UNC13D Intronic Variant Disrupting an NF-κB Enhancer in a Patient With Recurrent Macrophage Activation Syndrome and Systemic Juvenile Idiopathic Arthritis.

Authors:  Grant S Schulert; Mingce Zhang; Ammar Husami; Ndate Fall; Hermine Brunner; Kejian Zhang; Randy Q Cron; Alexei A Grom
Journal:  Arthritis Rheumatol       Date:  2018-05-02       Impact factor: 10.995

3.  Adult-Onset Still's Disease and Macrophage-Activating Syndrome Progressing to Lymphoma: A Clinical Pathology Conference Held by the Division of Rheumatology at Hospital for Special Surgery.

Authors:  Bella Mehta; Shanthini Kasturi; Julie Teruya-Feldstein; Steven Horwitz; Anne R Bass; Doruk Erkan
Journal:  HSS J       Date:  2018-03-26

Review 4.  Lymphoma presenting as secondary HLH: a review with a tale of two cases.

Authors:  Abhimanyu Ghose; Mahender Yellu; Trisha Wise-Draper; Divya Sharma; Julianne Qualtieri; Tahir Latif; Stephen Medlin
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-06-21

5.  UNC-45A Is a Nonmuscle Myosin IIA Chaperone Required for NK Cell Cytotoxicity via Control of Lytic Granule Secretion.

Authors:  Yoshie Iizuka; Frank Cichocki; Andrew Sieben; Fabio Sforza; Razaul Karim; Kathleen Coughlin; Rachel Isaksson Vogel; Riccardo Gavioli; Valarie McCullar; Todd Lenvik; Michael Lee; Jeffrey Miller; Martina Bazzaro
Journal:  J Immunol       Date:  2015-10-05       Impact factor: 5.422

6.  Lentiviral Gene Therapy for Familial Hemophagocytic Lymphohistiocytosis Type 3, Caused by UNC13D Genetic Defects.

Authors:  Sarah E Takushi; Na Yoon Paik; Andrew Fedanov; Chengyu Prince; Christopher B Doering; H Trent Spencer; Shanmuganathan Chandrakasan
Journal:  Hum Gene Ther       Date:  2020-06       Impact factor: 5.695

7.  The risk of hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type 2.

Authors:  Birthe Jessen; Sebastian F N Bode; Sandra Ammann; Subarna Chakravorty; Graham Davies; Jana Diestelhorst; Melissa Frei-Jones; William A Gahl; Bernadette R Gochuico; Matthias Griese; Gillian Griffiths; Gritta Janka; Christoph Klein; Tamara Kögl; Karin Kurnik; Kai Lehmberg; Andrea Maul-Pavicic; Andrew D Mumford; David Pace; Nima Parvaneh; Nima Rezaei; Geneviève de Saint Basile; Annette Schmitt-Graeff; Klaus Schwarz; Gulsun T Karasu; Barbara Zieger; Udo Zur Stadt; Peter Aichele; Stephan Ehl
Journal:  Blood       Date:  2013-02-12       Impact factor: 22.113

Review 8.  Gene hunting in the genomic era: approaches to diagnostic dilemmas in patients with primary immunodeficiencies.

Authors:  Craig Platt; Raif S Geha; Janet Chou
Journal:  J Allergy Clin Immunol       Date:  2013-10-05       Impact factor: 10.793

Review 9.  Evidence for defective Rab GTPase-dependent cargo traffic in immune disorders.

Authors:  Konrad Krzewski; Andrew R Cullinane
Journal:  Exp Cell Res       Date:  2013-06-26       Impact factor: 3.905

10.  Development of classical Hodgkin's lymphoma in an adult with biallelic STXBP2 mutations.

Authors:  Maciej Machaczka; Monika Klimkowska; Samuel C C Chiang; Marie Meeths; Martha-Lena Müller; Britt Gustafsson; Jan-Inge Henter; Yenan T Bryceson
Journal:  Haematologica       Date:  2012-10-25       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.